FDA Proposes Surgical Robotics Submission Guidance
Published
Draft guidance, not for implementation. Law checked through October 18, 2026.
Galen learned his surgery treating the gladiators of Pergamum, where the wound came first and the method followed. Modern device law reverses the order: the method must be demonstrated before the patient is opened. On September 24, 2026, the FDA issued a draft guidance titled "Robotically-Assisted Surgical Devices: Premarket Submissions," describing what the agency wants to see before such a system reaches an operating room.
The draft addresses teleoperated, software-controlled systems that help a practitioner position and control surgical instruments in open, minimally invasive, or endoluminal procedures. It sets out recommendations on non-clinical testing, including performance testing, on clinical data, and on labeling. Comments are due November 24, 2026, in docket FDA-2026-N-9505.
The legal weight sits elsewhere. A draft guidance states the agency's current thinking and binds no one. The duties that matter come from the Federal Food, Drug, and Cosmetic Act: device classification under 21 U.S.C. § 360c, the premarket pathway that classification dictates, and, for a connected system, the cyber-device requirements of § 360n-2. A sponsor that ignores the guidance is not in violation of it; a sponsor that cannot show a reasonable assurance of safety and effectiveness, by whatever evidence the guidance suggests or an equivalent route, will not reach the market.
Texas has a stake well beyond the regulatory desk. The state's academic medical centers and device companies develop and use these systems, and the draft's view of adequate testing will shape what plaintiffs argue a reasonable manufacturer should have done.
Limits
The draft may change before it is finalized. It does not alter Texas medical-practice rules, which continue to govern the surgeon at the console.